Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
25 May 2015 |
Main ID: |
NCT02175381 |
Date of registration:
|
21/06/2014 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC
|
Scientific title:
|
A Phase I/II Trial of the Carboplatin/Gemcitabine Combination as First Line Treatment for Elderly Patients With Stage IV NSCLC. |
Date of first enrolment:
|
February 2011 |
Target sample size:
|
69 |
Recruitment status: |
Completed |
URL:
|
http://clinicaltrials.gov/show/NCT02175381 |
Study type:
|
Interventional |
Study design:
|
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
Phase:
|
Phase 1/Phase 2
|
|
Countries of recruitment
|
Greece
| | | | | | | |
Contacts
|
Name:
|
Athanasios Karambeazis, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Medical Oncology Unit NIMTS (Veterans Hospital) |
|
Name:
|
Lambros Vamvakas, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
University Hospital of Herklion |
| |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Age =70 years old
- Cytologically or histologically documented NSCLC
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (at
least one measurable lesion)
- World Health Organisation (WHO) performance status 0-2
- Non-frail patients according to Comprehensive Geriatric Assessment
- Previously treated NSCLC (or patients for whom the combination is considered adequate
treatment) (for phase I part)
- No prior chemotherapy (for phase II part)
- Life expectancy of at least 12 weeks
- Serum bilirubin less than 1.5 times the upper normal limit
- Aspartate Aminotransferase and Alanine Aminotransferase less than 2.5 times the upper
normal limit in the absence of demonstrable liver metastases, or less than 5 times
the upper normal limit in the presence of liver metastases
- Serum creatinine less than 1.5 times the upper normal limit and Creatinine Clearance
>60 ml/min
- Neutrophil count more than 1.5x 109 /L
- Platelet count more than 100x 109 /L
- Before patient enrollment, written informed consent must be given according to Good
Clinical Practice guidelines and national/local regulations.
Exclusion Criteria:
- Hemoptysis
- Central nervous system metastases
- Clinically significant cardiovascular disease
- Medically uncontrolled hypertension
- Other co-existing malignancies or malignancies diagnosed within the last 5 years
(with the exception of basal cell carcinoma or cervical cancer in situ)
- Any evidence of severe uncontrolled concomitant disease (in the opinion of the
investigator)
Age minimum:
70 Years
Age maximum:
N/A
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
NSCLC
|
Intervention(s)
|
Drug: Carboplatin
|
Drug: Gemcitabine
|
Primary Outcome(s)
|
Overall Response Rate
[Time Frame: Disease evaluation at Week 8]
|
Secondary Outcome(s)
|
Overall Survival
[Time Frame: 1 year]
|
Safety Profile
[Time Frame: Every two weeks up to 12 weeks]
|
Disease control rate
[Time Frame: Disease evaluation at Week 8]
|
Progression Free Survival
[Time Frame: 1 year]
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|